Research data suggests that the triple-agonist approach may yield results that far surpass those of single or dual-agonist peptides, making it a focal point for obesity research
Moreover, BBR regulates the metabolic shift from fatty acid oxidation to glycolysis, reducing lipid deposition in renal tubular epithelial cells and alleviating renal tubulointerstitial damage (Rong et al., 2021)
All ingredients: Sea buckthorn water, glycerin, dipropylene glycol, propanediol, niacinamide, 1,2-hexanediol, caprylic/capric triglyceride, water, PG-13-decyl tetradeceth-24, hydroxyacetophenone, caprylyl glycol, hydrogenated lecithin, carbomer, glutathione (674 ppm), tromethamine, cetearyl alcohol, disodium EDTA, stearic acid, dipotassium glycyrrhizinate, Kakadu plum extract, butylene glycol, lecithin, pentylene glycol, acetylglutamine, sodium hyaluronate, folic acid, Bacillus thuringiensis/soybean ferment extract, oligopeptide-1, hexapeptide-11, oligopeptide-2, oligopeptide-3, hydrolyzed pea protein, madecassoside, phytosterols, squalane, oil Olive, Tocopherol, Polyglyceryl-10 Stearate, Panthenol, Hyaluronic Acid, Hydrolyzed Hyaluronic Acid, Hydroxypropyltrimonium Hyaluronate, Hydrolyzed Sodium Hyaluronate, Potassium Hyaluronate, Ceramide NP, Sodium Ascorbyl Phosphate, Shea Butter, Ethylhexylglycerin, Cross-linked Sodium Hyaluronate, Biotin, Pyridoxine, Cyanocobalamin, Riboflavin, Thiamine HCl, Retinol, Bioflavonoids, Acetyl Sodium Hyaluronate, Menadione, Acetyl Hexapeptide-8, Copper Tripeptide-1, Palmitoyl Pentapeptide-4, Linoleic Acid, Beta Carotene, Fragrance
J Clin Endocrinol Metab 80:13931398 Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG (1997) Two year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency
